Abstract:OBJECTIVE:To assess the efficacy and pathological change of fertility-sparing treatment with progestin for endometrial carcinoma (EC) of stage I a and complex atypical hyperplasia (CAH) and to observe the prognosis of the treatment.METHODS:Nine EC patients of stage I a and 21 CAH patients aged under 40 years who desired childbearing and retaining their fertility were enrolled into this study. All patients were given a daily oral high-dose of progestin with duration of treatment ranging from 6 to 9 months. Diagnostic curettage was performed every 3 months as a modality for seeing the histologic change of neoplastic tissues and endometrial tissue. A careful and long- term follow- up is necessary for patients with complete response (CR).RESULTS:During the first period of fertility-sparing management, according to histologic change, 5 EC patients and 18 CAH patients showed CR with no evidence of endometrial adenocarcinoma or hyperplasia, 2 EC patients and 2 CAH patients showed partial response with a regression to complex or simple hyperplasia without atypia, 2 EC patients and 1 CAH patient showed stable disease or progressive disease. Accordingly, a total of 26 patients showed CR (26 of 30 patients). The median time to CR was 6 months (range, 3 to 21 months) of progestin treatment. The median follow-up time was 55.5 months (range, 24 to 104 months) and all patients were alive. During follow-up, among the 26 patients with CR, 3 of 6 EC patients achieved CR recurred disease after a median time interval of 10 months (range, 6 to 51 months), 7 of 20 CAH patients achieved CR had recurrent disease after a median time interval of 12 months (range, 6 to 55 months). Four of 7 CAH with recurrent disease achieved CR to progestin re-treatment. Eight of 26 patients achieved CR continued a further 3 or 6 months of consolidation therapy, 3 of them had recurrent disease, the remaining 18 stopped progesterone treatment after CR and 7 patients had recurrent disease; there was no significant statistical difference between the two groups (P = 1.000). EC patients succeeded in 4 pregnancies, CAH patients succeeded in 10 pregnancies, they gave birth to 16 healthy babies in all.CONCLUSIONS:EC of stage I a and CAH had slow progression of symptoms. Progestin treatment in EC of stage I a and CAH patients was effective. A careful and long-term follow-up is required because of the substantial high rate of recurrence. Progestin re-treatment in most patients with recurrent endometrial cancer is effective and safe.

Risk Factors for Recurrence in Patients with Atypical Endometrial Hyperplasia and Endometrioid Adenocarcinoma after Fertility-Sparing Treatments

Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment

Fertility-preserving Treatment and Pregnancy Outcomes in the Early Stage of Endometrial Carcinoma.

Outcome of Conservative Treatment and Subsequent Assisted Reproductive Technology for Patients with Early-Stage Endometrial Adenocarcinoma and Poor Fertility Potential

Analysis of Pregnancy-Associated Factors after Fertility-Sparing Therapy in Young Women with Early Stage Endometrial Cancer or Atypical Endometrial Hyperplasia

Clinical Features and Outcome of 15 Patients with Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Received Primary Fertility-Sparing Therapy Followed by Hysterectomy

Analysis of Factors Associated With Recurrence of Early-Stage Endometrial Carcinoma and Atypical Endometrial Hyperplasia in Infertile Women After In Vitro Fertilization Treatment

Management of Recurrent Endometrial Cancer or Atypical Endometrial Hyperplasia Patients After Primary Fertility-Sparing Therapy

[Effects of Pathological Assessment of Endometrial Tissue in Fertility-Sparing Treatment with Progestin for Endometrial Carcinoma of Stage I a and Complex Atypical Hyperplasia].

Analysis of Risk Factors for Recurrence in Infertile Endometrial Cancer Patients after in Vitro Fertilization Treatment

Status and related factors of postoperative recurrence of ovarian endometriosis: a cross-sectional study of 874 cases

Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis

Risk Factors for Recurrence of Ovarian Endometriosis in Chinese Patients Aged 45 and Over

Insulin Resistance and Metabolic Syndrome Increase the Risk of Relapse for Fertility Preserving Treatment in Atypical Endometrial Hyperplasia and Early Endometrial Cancer Patients

[Analysis of Pregnancy Outcome after Fertility-Preserving Treatment among Women with Atypical Endometrial Hyperplasia or Endometrial Carcinoma].

Patterns of and Risk Factors for Recurrence in Women with Ovarian Endometriomas

[Clinical Analysis of Fertility-Sparing Therapy of Patients with Complex Atypical Hyperplasia and Endometrial Cancer].

Sparing Is Caring: Hormonal Retreatment in Women with Recurrent Endometrial Cancer after Fertility Preservation Management-A Single Centre Retrospective Study

Retreatment with progestin for recurrence after complete response with fertility-sparing treatment in patients with endometrial cancer

[Predictors of Recurrence and Prognosis in Patients with Stage I and II Endometrial Carcinoma].

Hysteroscopic Curettage Followed by Megestrol Acetate Plus Metformin As a Fertility-Sparing Treatment for Women with Atypical Endometrial Hyperplasia or Well-Differentiated Endometrioid Endometrial Carcinoma